The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality / Frank R. Lichtenberg.
Material type:![Text](/opac-tmpl/lib/famfamfam/BK.png)
- Hardcopy version available to institutional subscribers
Item type | Home library | Collection | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|---|
Working Paper | Biblioteca Digital | Colección NBER | nber w25328 (Browse shelf(Opens below)) | Not For Loan |
December 2018.
I investigate whether the types of cancer (breast, colon, lung, etc.) subject to greater penetration of new ideas had larger subsequent survival gains and mortality reductions, controlling for changing incidence. I use the MEDLINE/PubMED database, which contains more than 23 million references to journal articles published in 5400 leading biomedical journals, to construct longitudinal measures of the penetration of new medical ideas.
The 5-year survival rate is strongly positively related to the novelty of ideas in articles published 12-24 years earlier. This finding is consistent with evidence from case studies that it takes a long time for research evidence to reach clinical practice. The estimates suggest that about 70% of the 1994-2008 increase in the 5-year observed survival rate for all cancer sites combined may have been due to the increase in the novelty of medical ideas 12-24 years earlier.
The number of years of potential life lost from cancer before ages 80 and 70 are inversely related to the novelty of ideas in articles published 12-24 years earlier, conditional on incidence. The increase in medical idea novelty was estimated to have caused a 38% decline in the premature (before age 80) cancer mortality rate 12-24 years later.
Hardcopy version available to institutional subscribers
System requirements: Adobe [Acrobat] Reader required for PDF files.
Mode of access: World Wide Web.
Print version record
There are no comments on this title.